A woman checks into an emergency room with nausea, jaw pain, and fatigue. The attending physician runs a standard cardiac workup. The troponin comes back borderline. She is sent home. She returns by ambulance 6 hours later with a confirmed myocardial infarction. This is not a rare case. Women having heart attacks present without chest pain roughly 42% of the time, compared to 30% in men, yet the diagnostic criteria were built on male patient data collected over decades when women were routinely excluded from early-phase trials.
The FDA banned women of childbearing potential from Phase 1 and early Phase 2 trials from 1977 to 1993. Sixteen years of systematic exclusion. The downstream effect is that dosing standards for roughly 50% of common medications were set without adequate female pharmacokinetic data. Women metabolize drugs differently, clear them more slowly in many cases, and experience adverse drug reactions at nearly twice the rate of men. That 2-to-1 ratio is not a mystery. It is the predictable result of calibrating medicine to one sex and applying it to both.
The Consensus Problem
Medical guidelines move slowly by design. Peer review, replication, and cautious adoption exist for good reasons. But inertia dressed up as rigor is still inertia. The Liaison Committee on Medical Education dropped requirements for U.S. medical schools to teach health inequities in late March 2026, shifting to self-directed learning. Whatever the political motivation, the practical effect is that the next generation of physicians will have even less structured exposure to sex-based biological differences in clinical presentation.
The current debate over gender-affirming care for minors illustrates a related failure, though from a different angle. The American Society of Plastic Surgeons recommended in early 2026 that surgical interventions be deferred to age 19, citing evidence it described as "insufficient and of low certainty." The AMA initially appeared to agree, then disputed that characterization in a March 27 board newsletter. The NHS England report in 2025 advised "extreme caution" on hormonal therapy for minors. The HHS found no proven benefit from medical or surgical sex-reassignment for alleviating gender dysphoria in youth.
I will grant the AAP a fair point: gender dysphoria causes real suffering, and withholding care is not a neutral act. But "medically necessary" is a clinical claim that requires clinical evidence, not a consensus declaration. When the NHS and HHS both flag insufficient data, the honest response is to say the evidence base is thin, not to reaffirm guidelines as though the 2025 reports didn't happen.
What Sex-Stratified Data Actually Requires
The fix is not complicated to describe, even if it is expensive to execute. The NIH should require sex-stratified reporting as a condition of funding, not a recommendation. The FDA should mandate it for any drug seeking approval in a mixed-sex population. Medical school accreditation bodies should restore structured curriculum on sex-based biological differences, not leave it to self-directed learning that will predictably not happen.
The cost of running sex-stratified trials is real. Roughly 20-30% more participants, longer enrollment windows, higher per-trial budgets. Sponsors will push back. But the cost of not doing it is already visible in adverse drug reaction rates, missed cardiac diagnoses, and dosing standards that were never validated for half the people taking the medication.
The woman sent home from the emergency room did not need a policy debate. She needed a diagnostic protocol built on data that included her. Medicine has had the tools to collect that data for 30 years. The guidelines just haven't demanded it.
